Welcome to LookChem.com Sign In|Join Free

CAS

  • or

25658-36-0

Post Buying Request

25658-36-0 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

25658-36-0 Usage

General Description

Dimethyl 2,4-pyridinedicarboxylate is a chemical compound with the molecular formula C10H10N2O4. It is an ester of 2,4-pyridinedicarboxylic acid and is commonly used as a pharmaceutical intermediate in the synthesis of various drugs. This chemical is a colorless to light yellow liquid with a fruity odor, and it is insoluble in water but soluble in most organic solvents. Dimethyl 2,4-pyridinedicarboxylate is considered to be a relatively stable compound but may react violently with strong oxidizing agents. It is important to handle this chemical with care and follow proper safety protocols when working with it.

Check Digit Verification of cas no

The CAS Registry Mumber 25658-36-0 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,5,6,5 and 8 respectively; the second part has 2 digits, 3 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 25658-36:
(7*2)+(6*5)+(5*6)+(4*5)+(3*8)+(2*3)+(1*6)=130
130 % 10 = 0
So 25658-36-0 is a valid CAS Registry Number.
InChI:InChI=1/C9H9NO4/c1-13-8(11)6-3-4-10-7(5-6)9(12)14-2/h3-5H,1-2H3

25658-36-0SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 14, 2017

Revision Date: Aug 14, 2017

1.Identification

1.1 GHS Product identifier

Product name dimethyl pyridine-2,4-dicarboxylate

1.2 Other means of identification

Product number -
Other names Dimethyl 2,4-pyridinedicarboxylate

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:25658-36-0 SDS

25658-36-0Relevant articles and documents

Change of Orientation in Photoreaction by Oxygen. Effect of Oxygen on Photo-methoxylation of Dimethyl Ester of 2,4- and 3,4-Pyridinedicarboxylic Acid

Sugiyama, Toru,Kanai, Mitsuharu,Takenaka, Setsuko,Sugimori, Akira

, p. 1331 - 1332 (1985)

The UV-irradiation of dimethyl 2,4- and 3,4-pyridinedicarboxylates in methanol in the presence of H2SO4 under O2 brings about methoxylation at the β-position of the pyridine ring, while under N2 methoxylation occurs at the α-position.

Multiprotein Dynamic Combinatorial Chemistry: A Strategy for the Simultaneous Discovery of Subfamily-Selective Inhibitors for Nucleic Acid Demethylases FTO and ALKBH3

Das, Mohua,Yang, Tianming,Dong, Jinghua,Prasetya, Fransisca,Xie, Yiming,Wong, Kendra H. Q.,Cheong, Adeline,Woon, Esther C. Y.

supporting information, p. 2854 - 2867 (2018/09/25)

Dynamic combinatorial chemistry (DCC) is a powerful supramolecular approach for discovering ligands for biomolecules. To date, most, if not all, biologically templated DCC systems employ only a single biomolecule to direct the self-assembly process. To expand the scope of DCC, herein, a novel multiprotein DCC strategy has been developed that combines the discriminatory power of a zwitterionic “thermal tag” with the sensitivity of differential scanning fluorimetry. This strategy is highly sensitive and could differentiate the binding of ligands to structurally similar subfamily members. Through this strategy, it was possible to simultaneously identify subfamily-selective probes against two clinically important epigenetic enzymes: FTO (7; IC50=2.6 μm) and ALKBH3 (8; IC50=3.7 μm). To date, this is the first report of a subfamily-selective ALKBH3 inhibitor. The developed strategy could, in principle, be adapted to a broad range of proteins; thus it is of broad scientific interest.

DOPAMINE D3 RECEPTOR ANTAGONISTS COMPOUNDS

-

Page/Page column 123, (2016/05/19)

The disclosure is directed to novel dopamine D3 receptor antagonists, processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, including treating drug dependency and psychosis.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 25658-36-0